Genmab A/S (NASDAQ:GMAB) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Genmab A/S (NASDAQ:GMAB) have been assigned an average rating of “Moderate Buy” from the twelve research firms that are currently covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $42.17.

A number of brokerages have recently commented on GMAB. Leerink Partners upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective for the company in a research report on Thursday. BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday. Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research report on Thursday, January 23rd. Finally, Leerink Partnrs upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday.

Institutional Investors Weigh In On Genmab A/S

Institutional investors have recently made changes to their positions in the company. EverSource Wealth Advisors LLC raised its position in Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock valued at $26,000 after acquiring an additional 939 shares in the last quarter. Lindbrook Capital LLC raised its holdings in shares of Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after purchasing an additional 950 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after purchasing an additional 1,051 shares during the last quarter. Barclays PLC boosted its holdings in Genmab A/S by 1,072.8% in the fourth quarter. Barclays PLC now owns 2,498 shares of the company’s stock worth $52,000 after purchasing an additional 2,285 shares in the last quarter. Finally, Cromwell Holdings LLC increased its position in Genmab A/S by 656.8% during the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock worth $60,000 after buying an additional 2,496 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Price Performance

Shares of NASDAQ:GMAB opened at $21.30 on Friday. Genmab A/S has a 12 month low of $18.64 and a 12 month high of $31.88. The stock’s 50 day moving average price is $20.66 and its 200 day moving average price is $23.20. The stock has a market cap of $14.10 billion, a price-to-earnings ratio of 20.68, a PEG ratio of 0.54 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. On average, sell-side analysts expect that Genmab A/S will post 1.25 EPS for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.